Defective angiogenesis delays thrombus resolution: A potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 4, 2014, Pages 810-819

  Alias, Sherin ^a   Redwan, Bassam ^b   Panzenböck, Adelheid ^a   Winter, Max P ^a   Schubert, Uwe ^c   Voswinckel, Robert ^d   Frey, Maria K ^a   Jakowitsch, Johannes ^a   Alimohammadi, Arman ^a   Hobohm, Lukas ^a   Mangold, Andreas ^a   Bergmeister, Helga ^a   Sibilia, Maria ^a   Wagner, Erwin F ^e   Mayer, Eckhard ^f   Klepetko, Walter ^a   Hölzenbein, Thomas J ^g   Preissner, Klaus T ^c   Lang, Irene M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KLINIKUM IBBENBÜREN   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^e Centro Nacional de Investigaciones Oncológicas   (Spain)

^f KERCKHOFF HEART CENTER   (Germany)

^g Paracelsus Medical University Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CD31 ANTIGEN; CD45 ANTIGEN; CHLORDANE; CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PODOPLANIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ANEURYSM; ARTICLE; BLEEDING TIME; CAPILLARY DENSITY; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTROLLED STUDY; DNA SYNTHESIS; ENDARTERECTOMY; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBUS ANGIOGENESIS; VENOUS THROMBOEMBOLISM;

ENDOTHELIUM; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

AGED; ANGIOGENIC PROTEINS; ANIMALS; CELLS, CULTURED; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENDARTERECTOMY; FEMALE; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERTENSION, PULMONARY; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84897372440     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302991     Document Type: Article

References (42)

1. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation. 1997;96:2782-2784.
2. Lang IM, Moser KM, Schleef RR. Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism. Arterioscler Thromb Vasc Biol. 1998;18:808-815.
3. Cox JS. The maturation and canalization of thrombi. Surg Gynecol Obstet. 1963;116:593-599.
4. Henke PK, Wakefeld TW, Kadell AM, Linn MJ, Varma MR, Sarkar M, Hawley A, Fowlkes JB, Strieter RM. Interleukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res. 2001;99:84-91.
5. Waltham M, Burnand KG, Collins M, Smith A. Vascular endothelial growth factor and basic fbroblast growth factor are found in resolving venous thrombi. J Vasc Surg. 2000;32:988-996.
6. Modarai B, Burnand KG, Sawyer B, Smith A. Endothelial progenitor cells are recruited into resolving venous thrombi. Circulation. 2005;111:2645-2653.
7. Modarai B, Burnand KG, Humphries J, Waltham M, Smith A. The role of neovascularisation in the resolution of venous thrombus. Thromb Haemost. 2005;93:801-809.
8. Menéndez R, Nauffal D, Cremades MJ. Prognostic factors in restoration of pulmonary fow after submassive pulmonary embolism: a multiple regression analysis. Eur Respir J. 1998;11:560-564.
9. Lang IM. Chronic thromboembolic pulmonary hypertension-not so rare after all. N Engl J Med. 2004;350:2236-2238.
10. Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013;41:462-468.
11. Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J. 2000;15:440-448.
12. Bonderman D, Jakowitsch J, Redwan B, Bergmeister H, Renner MK, Panzenböck H, Adlbrecht C, Georgopoulos A, Klepetko W, Kneussl M, Lang IM. Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2008;28:678-684.
13. Wolf M, Boyer-Neumann C, Parent F, Eschwege V, Jaillet H, Meyer D, Simonneau G. Thrombotic risk factors in pulmonary hypertension. Eur Respir J. 2000;15:395-399.
14. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53:1211-1218.
15. Firth AL, Yao W, Ogawa A, Madani MM, Lin GY, Yuan JX. Multipotent mesenchymal progenitor cells are present in endarterectomized tissues from patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Cell Physiol. 2010;298:C1217-C1225.
16. Yao W, Firth AL, Sacks RS, Ogawa A, Auger WR, Fedullo PF, Madani MM, Lin GY, Sakakibara N, Thistlethwaite PA, Jamieson SW, Rubin LJ, Yuan JX. Identifcation of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009;296:L870-L878.
17. Bonderman D, Wilkens H, Wakounig S, Schäfers HJ, Jansa P, Lindner J, Simkova I, Martischnig AM, Dudczak J, Sadushi R, Skoro-Sajer N, Klepetko W, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33:325-331.
18. Morris TA, Marsh JJ, Chiles PG, Magaña MM, Liang NC, Soler X, Desantis DJ, Ngo D, Woods VL Jr. High prevalence of dysfbrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood. 2009;114:1929-1936.
19. Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation. 1994;89:2715-2721.
20. Varma MR, Moaveni DM, Dewyer NA, Varga AJ, Deatrick KB, Kunkel SL, Upchurch GR Jr, Wakefeld TW, Henke PK. Deep vein thrombosis resolution is not accelerated with increased neovascularization. J Vasc Surg. 2004;40:536-542.
21. Waltham M, Burnand KG, Collins M, McGuinness CL, Singh I, Smith A. Vascular endothelial growth factor enhances venous thrombus recanalisa-tion and organisation. Thromb Haemost. 2003;89:169-176.
22. Waltham M, Burnand K, Fenske C, Modarai B, Humphries J, Smith A. Vascular endothelial growth factor naked DNA gene transfer enhances thrombus recanalization and resolution. J Vasc Surg. 2005;42:1183-1189.
23. Modarai B, Humphries J, Burnand KG, Gossage JA, Waltham M, Wadoodi A, Kanaganayagam GS, Afuwape A, Paleolog E, Smith A. Adenovirus-mediated VEGF gene therapy enhances venous thrombus recanalization and resolution. Arterioscler Thromb Vasc Biol. 2008;28:1753-1759.
24. Haigh JJ, Morelli PI, Gerhardt H, Haigh K, Tsien J, Damert A, Miquerol L, Muhlner U, Klein R, Ferrara N, Wagner EF, Betsholtz C, Nagy A. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol. 2003;262:225-241.
25. Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB. Identifcation of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene. 1991;6:1677-1683.
26. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19:2003-2012.
27. Yao L, Yokota T, Xia L, Kincade PW, McEver RP. Bone marrow dysfunction in mice lacking the cytokine receptor gp130 in endothelial cells. Blood. 2005;106:4093-4101.
28. Motoike T, Loughna S, Perens E, Roman BL, Liao W, Chau TC, Richardson CD, Kawate T, Kuno J, Weinstein BM, Stainier DY, Sato TN. Universal GFP reporter for the study of vascular development. Genesis. 2000;28:75-81.
29. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol. 2001;230:230-242.
30. Liao Y, Day KH, Damon DN, Duling BR. Endothelial cell-specifc knockout of connexin 43 causes hypotension and bradycardia in mice. Proc Natl Acad Sci USA. 2001;98:9989-9994.
31. Patel AS, Smith A, Nucera S, et al. TIE2-expressing monocytes/macro- phages regulate revascularization of the ischemic limb. EMBO Mol Med. 2013;5:858-869.
32. Morimoto H, Takahashi M, Izawa A, Ise H, Hongo M, Kolattukudy PE, Ikeda U. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res. 2006;99:891-899.
33. Clauss M, Weich H, Breier G, Knies U, Röckl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996;271:17629-17634.
34. Schmeisser A, Garlichs CD, Zhang H, Eskaf S, Graffy C, Ludwig J, Strasser RH, Daniel WG. Monocytes coexpress endothelial and mac-rophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res. 2001;49:671-680.
35. Ali T, Humphries J, Burnand K, Sawyer B, Bursill C, Channon K, Greaves D, Rollins B, Charo IF, Smith A. Monocyte recruitment in venous thrombus resolution. J Vasc Surg. 2006;43:601-608.
36. McGuinness CL, Humphries J, Waltham M, Burnand KG, Collins M, Smith A. Recruitment of labelled monocytes by experimental venous thrombi. Thromb Haemost. 2001;85:1018-1024.
37. Ahmed Z, Bicknell R. Angiogenic signalling pathways. Methods Mol Biol. 2009;467:3-24.
38. Teng H, Chopp M, Hozeska-Solgot A, Shen L, Lu M, Tang C, Zhang ZG. Tissue plasminogen activator and plasminogen activator inhibitor 1 contribute to sonic hedgehog-induced in vitro cerebral angiogenesis. PLoS One. 2012;7:e33444.
39. Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Selman SH, Jankun J. Plasminogen activator inhibitor type-1 mutants regulate angio-genesis of human umbilical and lung vascular endothelial cells. Oncol Rep. 2004;12:1155-1162.
40. Tashiro Y, Nishida C, Sato-Kusubata K, et al. Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood. 2012;119:6382-6393.
41. Zabini D, Nagaraj C, Stacher E, Lang IM, Nierlich P, Klepetko W, Heinemann A, Olschewski H, Bálint Z, Olschewski A. Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction. PLoS One. 2012;7:e43793.
42. Sood V, Luke CE, Deatrick KB, Baldwin J, Miller EM, Elfine M, Upchurch GR Jr, Wakefeld TW, Henke PK. Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism. Thromb Haemost. 2010;104:1174-1183.